Current Edition


Merck’s Welireg scores FDA nod in cancers spurred by rare disease—and its label is broader than expected

Merck’s $1.1 billion bet on Peloton Therapeutics is starting to pay off. Belzutifan, one of the most lucrative assets Merck picked up through its 2019 …

Continue Reading →

Aeromics Initiates Phase 1 Clinical Trial Of CNS Edema Inhibitor AER-271 In Healthy Human Volunteers

Aeromics, Inc. (“Aeromics” or “the Company”), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people affected by disabling and life-threatening severe ischemic …

Continue Reading →